Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03402243 · ClinicalTrials.gov registry record · NA
Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use
A NA study of Tobacco Use Disorder, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT03402243: Completed NA study of Tobacco Use Disorder, sponsored by University of Minnesota.
NCT03402243 is a NA study of Tobacco Use Disorder that has completed, run by University of Minnesota. The registered enrollment target is 47 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03402243, a NA study of Tobacco Use Disorder, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
In this pilot study, menthol cigarette smokers will be randomized to one of three experimental marketplaces: 1) a condition simulating a ban on menthol cigarettes but not menthol e-cigarettes (condition A); 2) a condition simulating a ban on both menthol cigarettes and menthol e-cigarettes (Condition B); and 3) a condition in which menthol is not banned for either product (Condition C - the control condition). All conditions would have medicinal nicotine available if subjects decide to quit tobacco products entirely. At visits occurring every two weeks over a 6 week period, subjects will receive "credits" that they could exchange for any product available in their randomized marketplace condition. Outcomes include the amount of each tobacco product used.
Primary Outcome
Total number of cigarettes smoked and puffs of e-cigarettes used
Conditions Studied
Interventions
- OTHER Menthol ban on cigarettes
- OTHER Menthol ban on cigarettes and e-cigarettes
- OTHER No menthol ban
Study Locations (1)
Minnesota
- Clinical and Translational Sciences Institute - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-02-26 |
| Est. Completion | 2020-03-25 |
| Phase | NA |
What the finished NCT03402243 record still lists
NCT03402243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Menthol ban on cigarettes is the first listed.
NCT03402243 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03402243 about?
NCT03402243 is a clinical study titled "Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use". In this pilot study, menthol cigarette smokers will be randomized to one of three experimental marketplaces: 1) a condition simulating a ban on menthol cigarettes but not menthol e-cigarettes (condition A); 2) a condition simulating a ban on both menthol cigarettes and menthol e-cigarettes (Conditio...
What is the current status of trial NCT03402243?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2018-02-26. Estimated completion is 2020-03-25.
What conditions does trial NCT03402243 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT03402243?
The interventions under investigation include: Menthol ban on cigarettes (OTHER), Menthol ban on cigarettes and e-cigarettes (OTHER), No menthol ban (OTHER).
Who is sponsoring clinical trial NCT03402243?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03402243 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03402243's enrollment target sits among peer trials
47 56th of 70 higher than 15 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
Smoking Cessation Behavioral Treatment Study
RECRUITING · NA
-
Contingency Management for Veteran Smokers Undergoing Major Elective Surgery
RECRUITING · NA
-
A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder
RECRUITING · NA
-
Young Adult Tobacco/Nicotine and Cannabis Co-use
RECRUITING · NA
-
Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI